Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

The double-blind, Japanese Phase III S-CUBE trial in 334 patients with advanced HCC whose disease progressed after treatment with or who were intolerant to Nexavar sorafenib showed that S-1 missed the primary endpoint of improving OS vs. placebo. Taiho said it will make a decision regarding next steps for S-1 in HCC after the company completes its analysis of the data. ...